Howard Davis, Akamis Bio CEO
Tumor gene therapy developer rebrands, emerges with $30M from blue-chip investors
A transatlantic oncology outfit is entering 2023 with a new look, name, office space and $30 million to work with.
Akamis Bio — named after Akamas …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
